Clinical trial
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting…
NCT00092196 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092196 |
|---|---|
| Title | Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) |
| Official title | Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nausea, Vomiting, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | MK0869, aprepitant / Duration of Treatment: 3 days |
| Enrollment | 820 |
| Start date | Dec 1, 2002 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 24, 2004 |
| Last update posted | May 5, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: